Barclays PLC Merus N.V. Call Options Transaction History
Barclays PLC
- $327 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding MRUS
# of Institutions
188Shares Held
59MCall Options Held
345KPut Options Held
222K-
Rtw Investments, LP New York, NY4.17MShares$197 Million4.12% of portfolio
-
Commodore Capital LP New York, NY3.2MShares$151 Million16.98% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.75MShares$130 Million3.41% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA2.4MShares$113 Million0.34% of portfolio
-
Samlyn Capital, LLC New York, NY2.32MShares$110 Million2.45% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.16B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...